RxDoctor Payments Data

Jamie Loggins, MD

Surgery · Lewiston, MENPI 1346224003

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.6%), education and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Covidien LP at 54.5% of the total. Reporting peaked in 2020 at $30,746 and has fallen 96.0% since, to $1,224 in 2025. Among surgery clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$79,006in general payments, 2019–2025

Across 228 payments — averaging $346.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$43K
  • Intuitive Surgical$17K
  • Distalmotion US$7K
  • Fujifilm New Development USA, Inc.$5K
  • Medtronic$3K
  • W. L. Gore & Associates, Inc.$2K
  • plus $2K from 9 others

What the payments were for

  • Consulting fees$47,08360%
  • Travel & lodging$10,73814%
  • Food & beverage$9,65112%
  • Education$11,50015%
  • Gifts$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,006 in reported general payments places this provider in the 95th percentile of 138 surgery providers in Maine.

See all surgery providers in Maine

Medicare billing

Part B allowed, 2024
$12,184
Medicare patients
39
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$20,612
Sucralfate13$2,570
Ursodiol15$1,520
Enoxaparin Sodium12$969
Pantoprazole Sodium40$351
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$290
Ondansetron OdtOndansetron14$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$381$20,61223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 surgery providers in Maine.

Other surgery in Lewiston

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →